Eli Lilly and Company (LLY) rose sharply after reporting a strong Q1 2026 beat, lifting full-year guidance, and highlighting early momentum for its newly approved oral GLP-1 obesity pill, Foundayo. The move signals that investors still see Lilly’s obesity and diabetes franchise as a powerful growth engine, with Mounjaro, Zepbound, and Foundayo supporting a longer runway for revenue and earnings growth.
Eli Lilly and Company (LLY) rises sharply today after the drugmaker delivered a strong Q1 2026 report, lifted full-year guidance, and highlighted the FDA approval and launch momentum of its oral GLP-1 obesity pill, Foundayo. At 9:59 ET, shares were trading at $915.60, up 7.56%, a big move for a company with an $865.08B market cap and one that tells the market the GLP-1 growth story still has fuel.
Key Takeaways
LLY rises 7.56% to $915.60 in regular trading after Q1 2026 results beat on growth and management raised 2026 guidance.
The clearest catalyst is Lilly’s earnings update: Q1 revenue reached $19.8B, up 56% year over year, while reported EPS was $8.26 and non-GAAP EPS was $8.55.
Lilly now projects 2026 revenue of $82B to $85B and adjusted EPS of $35.50 to $37.00, a meaningful step up that supports the rally.
Mounjaro and Zepbound remain the core engine, and Foundayo adds a new oral GLP-1 growth lane that broadens Lilly’s obesity franchise.
For investors, the move reinforces that Lilly is still being valued as both a pharma heavyweight and a high-growth obesity and diabetes platform.
Why Eli Lilly and Company Stock Is Rising Today
The most likely reason for today’s jump is straightforward: Eli Lilly and Company (LLY) reported a beat-and-raise quarter. Q1 2026 revenue came in at $19.8B, up 56% year over year. Reported EPS reached $8.26, up 170%, while non-GAAP EPS was $8.55, up 156%.
Just as important, Lilly raised its full-year 2026 outlook. The company now expects $82B to $85B in revenue and adjusted EPS of $35.50 to $37.00. For a stock already priced for strength, guidance hikes matter more than polished corporate adjectives. They tell investors demand is running ahead of prior plans.
There was also a second positive driver in the same news cycle. Lilly highlighted FDA approval of Foundayo, its oral GLP-1 obesity drug orforglipron. That approval matters because it gives Lilly a pill-based option in a market that has been dominated by injectables. In plain English, it expands convenience and potentially widens the customer pool.
The market reaction started before the opening bell. Pre-market trading showed LLY at $896.70, up $45.29 or 5.32%. That early jump lines up with an earnings-driven move rather than a slow sentiment drift.
Mounjaro, Zepbound, and Foundayo Keep the GLP-1 Growth Engine Running
Lilly’s rally is not just about one quarter. It is about the products behind the quarter. Mounjaro was the main driver again, with worldwide revenue up 125% to $8.7B. Zepbound added $4.1B, up 80%. Those are huge numbers, and they show Lilly still has real commercial force in both diabetes and obesity.
This strength builds on an already powerful 2025 base. In 2025, Mounjaro sales rose 99% and Zepbound grew 175%, together generating $36.5B. In Q4 2025 alone, Lilly posted $19.3B in revenue, up 43%, with key products contributing $13.8B. So today’s move is not the market chasing a one-off headline. It is the market rewarding continued execution in the company’s most important franchise.
Foundayo adds another layer to that story. Lilly described it as the only approved GLP-1 pill that can be taken any time of day without food and water restrictions. That kind of convenience can matter in a category where adherence and ease of use shape long-term demand. Reuters-linked reporting also said Foundayo was prescribed 3,707 times in the U.S. in its second week after launch, which gives the launch narrative some real traction.
Moreover, broader access is improving. GoodRx said it was expanding access to Foundayo and Zepbound. That does not transform revenue overnight, but it helps support the view that Lilly is building a wider commercial moat around its GLP-1 portfolio.
How Eli Lilly and Company Financials and Valuation Look After the Move
Even after today’s rise, the financial backdrop explains why investors keep paying up for LLY. The stock trades at a P/E of 37.03, which is rich for traditional pharma but easier to justify when revenue is growing at 56% and the top products are still scaling fast. This is not being priced like a slow defensive drug stock. It is being priced like a category leader with a long runway.
There is also a quality angle here. Lilly’s market cap stands at $865.08B, beta is 0.504, and the dividend yield is 0.69%. That mix is unusual. Investors are getting growth-stock expansion with lower volatility than many pure biotech names. It is a rare setup, and the market rarely gives those away at a discount.
The earnings track record adds support. Lilly beat EPS estimates in 5 of the last 7 reported quarters before this one. On Feb. 4, 2026, it posted $7.54 versus a $7.17 estimate, a 5.2% beat. On Oct. 30, 2025, it earned $7.02 versus $6.37, a 10.2% beat. That pattern matters because repeated execution lowers the odds that today’s report is a fluke.
Wall Street is still broadly constructive. Analyst consensus stands at Buy, with 33 Buy ratings, 9 Hold ratings, and 3 Sell ratings. The consensus price target is $1,244.68, with a high target of $1,350. Morgan Stanley raised its target to $1,327 on April 10. Those targets were not today’s catalyst, but they show that the Street has stayed bullish into the move.
What Today’s LLY Rally Means for Investors
Today’s rally says the market still believes Lilly’s obesity and diabetes franchise is in expansion mode, not maturity mode. The guidance raise is the clearest proof. When a mega-cap company lifts its outlook while launching a new GLP-1 format, investors tend to reward both the near-term numbers and the longer growth runway.
That said, valuation still matters. LLY remains below its 52-week high of $1,132.06, but it is far above its 52-week low of $620.46. After a 7% plus move, chasing blindly is usually a poor habit. A more disciplined read is that Lilly remains one of the strongest large-cap growth stories in healthcare, but the stock still needs continued execution from Mounjaro, Zepbound, and Foundayo to keep justifying a premium multiple.
Sentiment also supports the trend. News sentiment over the last 7 days scored 0.7304, with 30-day sentiment at 0.7669 and 90-day sentiment at 0.769, all strongly positive. In other words, today’s jump did not come out of nowhere. It landed on top of an already favorable narrative, then added hard numbers to back it up.
Eli Lilly and Company (LLY) rises today because the company gave the market exactly what it wanted: fast growth, stronger guidance, and a fresh product catalyst in Foundayo. For investors, the message is simple. Lilly still looks like one of the few mega-cap healthcare names with both scale and genuine growth, which is why the stock keeps commanding attention when the numbers land.
LLY is rising after Eli Lilly posted a strong Q1 2026 beat, raised full-year revenue and EPS guidance, and highlighted launch progress for Foundayo. Investors are also reacting to continued strength in Mounjaro and Zepbound sales.
+Should I buy LLY stock now?
The article supports Lilly as a strong long-term growth story, but the stock still trades at a premium valuation after a sharp move higher. Investors may want to wait for a better entry point rather than chase the rally.
+What is driving Eli Lilly's growth?
The main growth drivers are Mounjaro and Zepbound, which continue to post very strong sales. Foundayo adds a new oral GLP-1 option that could broaden Lilly’s obesity franchise and extend its growth runway.
+Is Eli Lilly still a good long-term stock?
Yes, the company still looks like one of the strongest large-cap growth names in healthcare. Its earnings momentum, raised guidance, and expanding GLP-1 portfolio support the long-term case, though valuation remains a key risk.
Want the full picture on LLY?
Read the analyst-grade research report — charts, grades, and price targets.
